Related Experiment Videos
[Pathophysiologic aspects of diabetic angiopathy]
1Laboratoire de recherche en Biologie Vasculaire et Cellulaire, Paris.
Diabetes & Metabolism
|July 28, 1999
Summary
Blocking the receptor for advanced glycation end-products (RAGE) significantly reduced vascular lesions in diabetic mice. This suggests RAGE plays a key role in diabetic angiopathy, independent of blood sugar or lipid levels.
Area of Science:
- Endocrinology
- Vascular Biology
- Metabolic Diseases
Background:
- Diabetes mellitus frequently leads to vascular complications.
- Hyperglycaemia in diabetes causes metabolic alterations and advanced glycation end-product (AGE) formation.
- AGEs interact with receptors for advanced glycation end-products (RAGE), creating a feedback loop that increases RAGE expression.
Purpose of the Study:
- To investigate the role of RAGE in the pathophysiology of diabetic angiopathy.
- To determine if blocking RAGE can ameliorate atherosclerosis in a diabetic mouse model.
Main Methods:
- Utilized genetically-manipulated mice with accelerated atherosclerosis and diabetes.
- Administered a soluble, truncated form of RAGE to block cell surface RAGE.
- Assessed the impact of RAGE blockade on vascular lesion formation.
Main Results:
- Complete suppression of enhanced vascular lesion formation was observed in diabetic mice treated with soluble RAGE.
- The improvement in atherosclerosis occurred without significant changes in plasma lipids or glycaemia.
- This highlights a lipid- and glycemia-independent mechanism contributing to atherogenesis in diabetes.
Conclusions:
- RAGE plays a critical role in the development of diabetic angiopathy and atherosclerosis.
- Targeting RAGE with soluble forms offers a potential therapeutic strategy for diabetic vascular complications.
- The RAGE-mediated pathway contributes to atherogenesis independently of hyperglycemia and dyslipidemia.